Puma Biotechnology: A Speculative Investment At A Discount (NASDAQ:PBYI) | Seeking Alpha
10 Takeover Targets of 2018
Puma Biotechnology
Puma Bio: Now Or Never. I Go With Never (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology | $PBYI Stock | Shares Climb Up as Company Announced FDA Approval for NERLYNX - Warrior Trading News
Puma and CANBridge cancel licensing deal for $20m
Puma Biotechnology: A Speculative Investment At A Discount (NASDAQ:PBYI) | Seeking Alpha
Puma Biotech punts near $300 million on Takeda discard
Puma Biotech's new cancer drug Nerlynx suffered a terrible quarter. What gives? | Fierce Pharma
Opinion: 5 biotech stocks that could be the next big winners - MarketWatch
A Licensing Agreement Won't Protect This Biotech From A Takeover | Investor's Business Daily
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
5 Best Biotech Stocks for 2018 | InvestorPlace
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Why Puma Biotechnology Is Soaring Today | The Motley Fool
UBS Has Nine Biotech Buyout and Merger Candidates – 24/7 Wall St.
Goldman Recommends Selling Puma Biotech, Clovis Oncology; Cites Company-Specific, Competitive Risks
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology: Who Are They? What Happened? And, Where Are They Going? (NASDAQ:PBYI) | Seeking Alpha
The Daily Biotech Pulse: IPOs, Puma's Breast Cancer Drug Gets Label Expansion, Buyout Offer For Organovo
With 53% institutional ownership, Puma Biotechnology, Inc. (NASDAQ:PBYI) is a favorite amongst the big guns | Nasdaq
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Puma pounces on failed Takeda drug, snapping up cancer prospect
